 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LTI-03 / Aileron
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date: A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients (clinicaltrials.gov) - Nov 13, 2024
P1, N=24, Active, not recruiting, Sponsor: Lung Therapeutics, Inc
Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- LTI-03 / Lung Therap
Caveolin Scaffolding Domain peptide LTI-03 Modulates Inflammatory and Fibrotic Responses in Aged Mice After Bleomycin Challenge (Silfurberg A) - Nov 8, 2022 - Abstract #ICLAF2022ICLAF_173;
Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 LTI-03-DPI reduced inflammatory and profibrotic parameters in the aged BLM model.
- ||| LTI-03 / Aileron
Trial completion: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - Mar 7, 2022
P1, N=71, Completed, Sponsor: Lung Therapeutics, Inc
LTI-03-DPI reduced inflammatory and profibrotic parameters in the aged BLM model. Recruiting --> Completed
- LTI-03 / Lung Therap
Caveolin Scaffolding Domain LTI-03 Modulates Both Inflammatory and Fibrotic Responses in Aged Mice After Bleomycin Challenge (Room 212-214 (South Building, Level 2), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_2094;
Taken together, the LTI-03-DPI reduced both inflammatory and profibrotic parameters in an aged mouse model of BLM lung injury and fibrosis. Effects of LTI-03 on pSMAD2/3 expression in this model were consistent with effect of LTI-03 on SMAD phosphorylation in primary IPF fibroblasts.Funding: Lung Therapeutics.
- ||| LTI-03 / Aileron
Enrollment open: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - Sep 9, 2021
P1, N=72, Recruiting, Sponsor: Lung Therapeutics, Inc
Effects of LTI-03 on pSMAD2/3 expression in this model were consistent with effect of LTI-03 on SMAD phosphorylation in primary IPF fibroblasts.Funding: Lung Therapeutics. Suspended --> Recruiting
- LTI-03 / Lung Therap
[VIRTUAL] The Role of LTI-03 in Lung Fibrosis () - Jul 31, 2021 - Abstract #IPFSummit2021IPF_Summit_25;
- LTI-03 / Aileron
Trial completion date, Trial primary completion date: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - May 11, 2021
P1, N=56, Suspended, Sponsor: Lung Therapeutics, Inc
Suspended --> Recruiting Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||| LTI-03 / Aileron
Trial suspension: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - Oct 26, 2020
P1, N=56, Suspended, Sponsor: Lung Therapeutics, Inc
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Suspended
- || LTI-03 / Aileron
Trial completion date, Trial primary completion date: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - May 13, 2020
P1, N=56, Recruiting, Sponsor: Lung Therapeutics, Inc
Recruiting --> Suspended Trial completion date: Aug 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- ||| LTI-03 / Aileron
Enrollment open: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - Feb 24, 2020
P1, N=56, Recruiting, Sponsor: Lung Therapeutics, Inc
Trial completion date: Aug 2020 --> Dec 2020 | Trial primary completion date: Jul 2020 --> Nov 2020 Not yet recruiting --> Recruiting
- ||| LTI-03 / Aileron
New P1 trial: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects (clinicaltrials.gov) - Jan 18, 2020
P1, N=56, Not yet recruiting, Sponsor: Lung Therapeutics, Inc
- LTI-03 / Lung Therapeutics
Late Breaking Abstract - Caveolin-1 derived peptide LTI-03 promotes epithelial cell survival and attenuates pulmonary fibrosis (TP-37) - Aug 26, 2019 - Abstract #ERS2019ERS_5810;
Furthermore, AEC2 cell markers ABCA3 and SPC were increased. LTI-03’s anti-fibrotic effects on both epithelial and fibroblasts render it a strong candidate for IPF therapy.